Inhibrx Biosciences, Inc. (INBX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Mark Paul Lappe | Founder, CEO & Chairman | 1.13M | -- | 1967 |
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive VP, CFO & Treasurer | 2.19M | -- | 1980 |
| Mr. David J. Matly M.B.A. | President and Chief Commercial & Business Development Officer | -- | -- | 1986 |
| Ms. Bonne Adams M.B.A. | Vice President of Operations | -- | -- | 1977 |
| Dr. Ashraf Amanullah Ph.D. | Executive VP & Chief Technical Operations Officer | -- | -- | 1968 |
| Dr. Carlos Bais Ph.D. | EVP & Chief Scientific Officer | -- | -- | -- |
| Ms. Leah Pollema J.D. | VP, General Counsel & Corporate Secretary | -- | -- | -- |
| Dr. Josep Garcia Ph.D. | Executive VP & Chief Clinical Development Officer | -- | -- | -- |
Inhibrx Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 156
Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Corporate Governance
Upcoming Events
March 17, 2025 at 8:05 PM UTC
Inhibrx Biosciences, Inc. Earnings Date
Recent Events
April 17, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
March 17, 2025 at 12:00 AM UTC
POS EX: Post-effective amendment filed solely to add exhibits to a registration statement
June 14, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission